In heart failure with reduced ejection fraction (HFrEF), renin-angiotensin system inhibitors (RASi) improve morbidity and mortality. However, patients aged >80 years constituted a small minority in trials. We assessed the association between RASi use and mortality/morbidity in HFrEF patients aged >80 years. 
Introduction
Activation of the renin-angiotensin-aldosterone system (RAAS) is a key feature of heart failure (HF). 1 Targeting components of RAAS has been a successful therapeutic strategy in HF with reduced ejection fraction (HFrEF). Indeed, randomized clinical trials (RCTs) in HFrEF have shown significantly improved mortality/morbidity in patients treated with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). [2] [3] [4] [5] [6] [7] Heart failure is an aging-related disease. 8, 9 Mean age of HF patients is >70 years in most developed countries. Additionally, the HF prevalence rises with age, from 2% in the general population to >10% among people >70 years of age. 8, 9 Although octogenarians represent a substantial and growing proportion of the HF population, they have been excluded from or are under-represented in RCTs. 10 They have more comorbidity and frailty but also greater risk of cardiovascular events. Thus, the use of and, in particular, the potential efficacy and safety of HF medications remains uncertain. Therefore, in patients with HFrEF and age >80 years, we assessed use of renin-angiotensin system inhibitors (RASi) and tested their association with all-cause mortality, all-cause mortality/HF hospitalization, and as a potential marker of safety, also syncope-related hospitalization.
Methods

Study protocol and setting
The Swedish Heart Failure Registry (SwedeHF; www.SwedeHF.se) has been previously described. 11 The only inclusion criterion is clinicianjudged HF. Approximately 80 variables are recorded at discharge from hospital or after an out-patient clinic visit. The Swedish Board of Health and Welfare (www.socialstyrelsen.se) administers the Population Registry and the Patient Registry. The Population Registry provided date of death. From the Patient Registry, we obtained additional baseline comorbidities and the outcomes hospitalization due to HF, hospitalization due to syncope, and hospitalization due to pneumonia/influenza/other respiratory infections, defined according to ICD-10 codes, and causes of death (where we used underlying cause rather than immediate mode of death).
Statistics Sweden (www.scb.se) provided socioeconomic characteristics. The Swedish personal identification number allows linking of diseasespecific health registries and governmental health and statistical registries.
Establishment of the HF registry and this analysis with linking of the above registries were approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out.
Patients
Patients registered in SwedeHF between 11 May 2000 (the start of the registry) and 31 December 2012, with age >80 years, EF < 40%, and no missing data for ACEi and ARB use, were included. If the same patient was registered more than once, the first registration was selected. Patients who died during the hospitalization that prompted to their first SwedeHF registration were excluded. Index date was defined as the date of the hospital discharge (if inpatient) or of outpatient clinic visit. End of the follow-up was 31 December 2012. A 'positive control' consistency analysis was performed in patients aged < _80 years, more comparable to those enrolled in RCTs. A 'negative control outcome' consistency analysis was performed in the cohort of patients aged >80 years using the occurrence of a hospitalization for pneumonia/influenza/other respiratory infections as outcome, since this is not expected to be associated with RASi use (the exposure).
Statistical analyses
The propensity score for treatment with RASi was calculated for each patient by a logistic regression model including 37 covariates as independent variables and RASi use as the dependent variable, with continuous variables modelled as restricted cubic splines (three knots at fixed percentiles of the distribution). Missing data were handled by multiple imputation using chained equations (10 imputed datasets generated). Variables included in the imputation models and those considered for calculating propensity scores are marked in Table 1 .
Thereafter, a propensity score matched cohort of patients receiving vs. not receiving RASi was generated by 1:1 matching with caliper <0.01 and no replacement. In order to handle the presence of missing data, propensity scores were calculated for each patient across the 10 imputed datasets, averaged, and then matching was performed using the averaged scores to estimate the treatment effect. 12 The ability of the matching to balance the propensity scores across the study arms was assessed by a density plot. The ability of matching to balance baseline characteristics was assessed by absolute standard differences, where a value <10% is considered not significant. 13 Outcomes for this study were all-cause mortality, the composite of allcause mortality and HF hospitalization, and hospitalization due to syncope. Survivor functions in RASi vs. non-RASi users were estimated using the non-parametric Kaplan-Meier method. The use of this method in the propensity score-matched cohort represents adjustment for confounders. However, since matching reduces the sample size and may limit generalizability, we also conducted a consistency analysis where Cox proportional hazard models were fitted in the overall cohort including propensity scores as a covariate. The proportional-hazards assumption was tested on the basis of Schoenfeld residuals and met.
Interactions between RASi use and clinically relevant variables for allcause mortality and the composite of all-cause mortality and HF hospitalization was assessed by Cox proportional hazard models within the matched cohort and displayed in a Forest plot.
All the statistical analyses were performed by Stata 14.2 (StataCorp LLC, College Station, TX, USA). A P-value <0.05 was considered statistically significant.
Results
Between 11 May 2000 and 31 December 2012, there were 80 772 registrations in SwedeHF. After the exclusion of registrations with missing or preserved/mid-range (> _40%) EF, follow-up time < _0, or missing data for RASi use, 40 268 registrations from 24 552 unique patients were left.
The main analysis was performed in 6710 patients aged >80 (27% of the HFrEF population fulfilling the inclusion criteria). After propensity score matching, the analysis was restricted to 2416 patients, 1208 (50%) treated and 1208 (50%) untreated. A flow chart describing patients' selection is reported in Supplementary material online, Figure S1 .
Baseline characteristics
In the overall population aged >80 years, median age was 85 [interquartile range (IQR) 82-87], 38% were women. Of these, 5384 (80%) patients were receiving RASi and 1326 (20%) were not. Of RASi-treated patients, 29% received target dose (or higher) or a combination of ACEi and ARB, whereas 31% received 50-99% of target dose, and the remaining 40% received less than 50% of the target dose (target doses reported in Supplementary material online, Table  S1 ). Treated and untreated patients differed with respect to most baseline characteristics (see Supplementary material online, Table  S2) , with younger age, more specialist care, less severe HF, better renal function and use of treatments (except for MRA), and less comorbidities in those receiving RASi. Consequently, also the distributions of the propensity scores were significantly different in RASi vs. non-RASi users ( Figure 1 ). After matching, there were no statistically significant differences in baseline characteristics between RASi and non-RASi users, with standardized differences <10% for all variables except for NT-proBNP (13%), and propensity score distributions were well matched ( Figure 1) . Of RASi patients included in the matched cohort, 22% received target dose (or higher) or a combination of ACEi and ARB, whereas 31% received 50-99% of target dose, and the remaining 47% received less than 50% of the target dose.
Outcome analysis
Overall mortality In the overall cohort, over a median follow-up of 1.4 (IQR 0. P-values for differences in baseline characteristics between RASi and non-RASi user were all not statistically significant and thus have been omitted. Standardized difference is defined as the difference in means or proportions or ranks divided by the mutual standard deviation. BMI, body mass index; CRT, cardiac resynchronization therapy; EF, ejection fraction; eGFR, estimated glomerual filtration rate (calculated by MDRD formula); HF, heart failure; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RASi, renin-angiotensin system inhibitor; SD, standard difference; TIA, transient ischaemic attack. The consistency analysis performed in the overall cohort adjusting for (rather than matching by) the propensity score, yielded a HR = 0.77 (95% CI 0.71-0.83) in RASi vs. non-RASi users.
Composite outcome
In the overall cohort, crude survival free from HF hospitalization was 56% (95% CI 55-57) and 34% (95% CI 31-37) at 1 year and 31% (95% CI 30-32) vs. 16% (95% CI 14-18) at 3 years in RASi vs. nonRASi users, respectively, with 452 (95% CI 438-467) vs. 878 (95% CI 828-932) events per 1000 patient-years (P < 0.001) and unadjusted HR = 0.58 (95% CI 0.54-0.62) (Take home figure) .
In the matched cohort, 1-year survival free of HF hospitalizations was 44% (95% CI 41-47) vs. 36% (95% CI 33-39) in treated vs. untreated patients, with an 8% absolute risk reduction and 12 patients needed to treat to prevent one event. Three-year outcome free risk was 21% (95% CI 19-23) vs. 17% (95% CI [15] [16] [17] [18] [19] [20] in RASi vs. nonRASi users. Rates for mortality/HF hospitalization were 672 (95% CI 631-716) vs. 826 (95% CI 776-879) per 1000 patient-years (P < 0.001), with HR = 0.86 (95% CI 0.79-0.94).
The model adjusted for propensity score run in the overall population yielded to HR = 0.84 (95% CI 0.78-0.90).
Hospitalization due to syncope
In the overall cohort, crude 1-year risk of hospitalization due to syncope was 1.9% (95% CI 1.5-2.3) vs. 1.2% (95% CI 0.7-2.1) in treated vs. untreated patients, respectively. Event rates were 14.7 (95% CI 12.6-17.2) vs. 14.9 (95% CI 10.0-22.0) per 1000 patient-years (P = 0.95), respectively, and unadjusted HR = 1.04 (95% CI 0.68-1.59).
In the matched cohort, 1-year risk of hospitalization due to syncope was 2.0% (95% CI 1.2-3.1) in treated vs. 1.3% (95% CI 0.7-2.3) in untreated patients. Event rates were 13.0 (95% CI 8.8-19.1) vs. 15.6 (95% CI 10.6-23.1) per 1000 patient-years (P = 0.51), respectively, with HR = 0.87 (95% CI 0.50-1.51).
The model adjusted for propensity score run in the overall population yielded a HR = 0.94 (95% CI 0.60-1.47). Figure 2 reports the associations between RASi use and all-cause death and all-cause death/HF hospitalization in clinically relevant subgroups. There was a significant interaction between RASi use and ischaemic heart disease for the composite of mortality/HF hospitalization, with RASi associated with lower risk in patients with vs. without concomitant ischaemic heart disease.
Subgroup analysis
Positive control analysis
In the positive control analysis in age < _80 years, where RASi are known to be effective, there were 17 842 patients. Of these 16 709 (94%) were treated by RASi and 1133 (6%) were not. Baseline characteristics in the overall and matched cohort are reported in Supplementary material online, Table S3 . Median age was 69 (IQR 61-75) years, 25% were women. In the RASi vs. non-RASi arm, there were 91 (95% CI 88-94) vs. 232 (95% CI 215-251) deaths per 1000 patient-years (P < 0.001) yielding an unadjusted HR = 0.40 (95% CI 0.37-0.43), whereas event rates for the composite outcome were 223 (95% CI 219-228) vs. 426 (95% CI 397-457) per 1000 patientyears yielding an unadjusted HR = 0.57 (95% CI 0.53-0.61) (Take home figure) , and those for hospitalization due to syncope were 8.7 (95% CI 7.9-9.6) vs. 9.2 (95% CI 6.1-13.7) per 1000 patient-years (P = 0.81) yielding an unadjusted HR = 0.97 (95% CI 0.64-1.47). Cause of death was cardiovascular in 3449 (65%), with the same proportions in RASi and non-RASi users.
After propensity score matching, the analysis was restricted to 2126 patients, with 1063 (50%) of them receiving RASi. One-year survival was 80% (95% CI 77-82) and 74% (95% CI 71-77), whereas 1-year survival free of HF hospitalization was 59% (95% CI 56-62) and 52% (95% CI 49-55) in RASi vs. non-RASi users, respectively. Thus, the 1-year absolute risk reduction was 6% for mortality and 7% for the composite outcome, with 17 and 14 patients needed to prevent one event, respectively. In the RASi vs. no RASi group, event rates were 175 (95% CI 160-191) vs. 219 (95% CI 202-238) per 1000 patient-years for overall mortality, and 336 (95% CI 311-362) vs. 404 (95% CI 375-434) for the composite, respectively (P < 0.001). RASi vs. non-RASi had HR = 0.81 (95% CI 0.71-0.91) for overall mortality and 0.85 (95% CI 0.76-0.94) for the composite outcome (Take home figure) . Cause of death was cardiovascular in 694 (66%) patients [331 (67%) in RASi and 363 (64%) in non-RASi]. Finally, 1-year risk of hospitalization due to syncope was 1.7% (95% CI 1.0-2.7) vs. 0.9% (95% CI 0.5-1.8) and event rates were 10.5 (95% CI 7.3-15.1) vs. 9.1 (6.0-13.6) per 1000 patient-years (P = 0.61) in treated vs. untreated patients, respectively, yielding to HR = 1.16 (95% CI 0.67-2.01). Figure 1 Propensity scores distribution in the matched and overall cohorts of patients aged >80 years. The distributions of propensity scores are reported in renin-angiotensin system inhibitor vs. non-renin-angiotensin system inhibitor users and displayed by Kernel density plots. In the overall population, treated patients had a considerably greater propensity for treatment, whereas as in the matched population, the propensity scores were nearly identically distributed. RASi, renin-angiotensin system inhibitor. 
Negative control outcome analysis
In the matched cohort of patients aged >80 years, event rates for hospitalization due to pneumonia/influenza/other respiratory infections were 78 (95% CI 67-92) per 1000 patient-years in RASi vs. 81 (95% CI 68-78) in non-RASi (P = 0.83), yielding an HR = 1.00 (95% CI 0.79-1.28).
Discussion
Among patients in SwedeHF with HFrEF, 27% were >80 years old, with 80% receiving RASi (compared with 94% in age < _80). RASi use was independently associated with similar relative risk reduction of outcomes in both age categories, but with greater absolute risk reduction in older patients, suggesting RASi to be similarly, or potentially even more beneficial, in age >80 years. Furthermore, relative risk reduction in outcomes associated with RASi use in positive controls (aged < _80) was similar to that observed in trials (20%), suggesting, but not proving, that similar results that we observed in patients aged >80 might potentially be seen in an RCT setting. RASi use did not appear associated with increased risk of syncope-related hospitalization, regardless of age.
Renin-angiotensin system inhibitors use in age >80 years European Society of Cardiology (ESC) guidelines on HF recommend RASi in HFrEF patients regardless of age. 9 In our real-world HFrEF population, we observed that 20% of patients aged >80 vs. 6% of those aged < _80 years did not receive RASi, with comparable RASi non-use observed in the octogenarian HFrEF (also EF 40-45% included) subpopulation of the Euro Heart Survey II (18%) 8 and of
Get With the Guidelines-HF (GWTG-HF) programme (21%), 14 but lower than in the West Tokyo HF registry (40%). 15 One of the potential reasons for less RASi use in older vs. younger patients observed in our study may be the more impaired renal function, where these agents may be avoided in patients not tested in RCTs (estimated glomerual filtration rate, eGFR < 30 mL/min/ 1.73 m 2 or hyperkalaemia). However, in a previous analysis from Take home figure The Kaplan-Meier curves for time to all-cause mortality and time to all-cause mortality/heart failure hospitalization in renin-angiotensin system inhibitor vs. non-renin-angiotensin system inhibitor users in the matched and overall cohorts with age >80 (A) and < _80 years (B; positive control analysis). Event rates were higher in age >80 (A) vs. age < _80 years (B). The risk was dramatically lower in treated vs. untreated patients overall, which may be due to confounding (solid lines), but was lower also after propensity score matching. The relative risk reduction was similar in age >80 and < _80 years but the absolute risk reduction was greater in the older cohort.
. SwedeHF focusing on chronic kidney disease, 66% of HFrEF patients with eGFR < 30 mL/min/1.73 m 2 were treated with RASi agents, suggesting that trial criteria for low eGFR is not a strong deterrent for RASi use or at least for RASi continuation during eGFR decline. 13 Less RASi use in the elderly may also be explained by comorbidity, frailty, aversion toward polypharmacy, less specialist care, and social circumstances (i.e. more elderly patients live alone). 10 But there are also studies suggesting older age per se as a reason for RASi and other HF therapy underuse and underdosing. 14, [16] [17] [18] [19] However, clinicians may also avoid RASi agents because of the lack of trial evidence of RASi efficacy and safety in octogenarians.
Association between renin-angiotensin system inhibitors use and outcomes in age >80 years
Octogenarians have been vastly under-represented in HFrEF trials, 10 although they do not represent a minority in real world, with 27% of the SwedeHF HFrEF population aged >80 and 15% of patients enrolled in GTWG-HF aged >85 years. 14 Indeed, in SOLVD inclusion criterion was age <80 years, 6 whereas mean age in CONSENSUS was 71. 7 Mean age ± standard deviation was 63 ± 11 years in ValHeFT, 64 ± 11 in CHARM-Added, and 66 ± 11 in CHARMAlternative. [3] [4] [5] Under-representation in trials may be linked to less referral to cardiology specialist care limiting the likelihood to be enrolled in trials, and to age-related conditions that are often exclusion criteria in RCTs (i.e. cancer, anaemia, chronic kidney disease, cerebrovascular disease). Consequently, treatments recommended in guidelines are based on RCTs enrolling younger patients, with different phenotypes and concomitant therapies. RASi represent the cornerstone of HFrEF therapy, but there are contrasting data about their role in improving outcomes in octogenarians. 20 In a meta-analysis of four RCTs enrolling patients with left ventricular dysfunction, ACEi use improved survival in patients with age < _ but not >75 years. 2 However, only 1066 patients were aged >75 years vs. 11 674 aged < _75, and there was no significant Figure 2 A forest plot reporting hazard ratios for renin-angiotensin system inhibitors in pre-specified subgroups in the matched cohort aged <80 years, with P-values for interactions. EF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate (calculated by MDRD formula); HF, heart failure; NYHA, New York Heart Association.
Association between RASi use and mortality/morbidity in HFrEF patients interaction between age and ACEi. 2 Conversely, small observational studies reported signals for RASi associated with improved outcomes. 21, 22 Moreover, in the subgroup of patients aged > _80 years enrolled in the Euro Heart Survey II, RASi was associated with reduced mortality regardless of EF. 8 In a larger study enrolling the HFrEF cohort of the US National Heart Care project, ACEi use was associated with improved 1-year mortality, with a trend towards higher benefit in oldest patients. 19 SwedeHF includes one of the largest HF octogenarian cohorts worldwide. This allowed investigation of the association between RASi use and outcomes in an adequately powered population, adjusting for numerous potential confounders and performing for the first time a propensity score-matched analysis in this setting. We showed comparable HRs for mortality and mortality/HF hospitalization in the age > 80 years subpopulation and in the positive control cohort aged < _80. Notably, the HRs for mortality were similar to those in RASi trials, suggesting that similar results might be reproduced in a RCT setting. Additionally, we reported that only 53% of our elderly population received > _50% of the target dose for RASi, leading to hypothesize that the magnitude of the association between RASi and outcome shown in our analysis may be even underestimated. This might be also supported by the greater absolute risk reduction of outcomes in age >80 vs. < _80 years, that might be explained by the higher mortality/morbidity in the first vs. the latter subgroup. However, the greater risk reduction for mortality than for the composite endpoint, and the relatively larger risk reduction despite lower dosing than in trials, may also be explained by unmeasured confounders. Finally, a major concern for RASi use in HF elderly patients may be the potentially increased risk of hypotension and syncope. Indeed, age-related changes as reduction in body mass and total body water may result in lower distribution volume and higher plasma concentration of hydrophilic RASi. However, in our analyses we did not observe any association between RASi use and risk of hospitalization due to syncope, but we did observe reassuring data on mortality, 23 leading to hypothesize that RASi may be safe in also in very old patients.
Limitations
Although SwedeHF collects many variables and allowed us to perform extensive adjustment by a propensity score-matched design, as confirmed by the negative control outcome analysis, we cannot definitively rule out potential unmeasured confounders. Indeed, RASi use was defined as at baseline and thus there could have been crossover throughout the follow-up that may have diluted the association with outcomes. Additionally, non-RASi patients might have received RASi prior to the enrolment in SwedeHF, but then have interrupted because of tolerance/adherence issues or worsening health/harms related to comorbid conditions. Furthermore, SwedeHF reports data on prevalent but not incident RASi use. However, RASi use may be more likely to be incident in patients with more recent HF onset, and in our analysis we reported no interaction between treatment use and HF duration. Thus, it may be hypothesized similar association between prevalent/incident RASi use and outcomes. HFrEF was defined as EF < 40% at the assessment closest to the first SwedeHF registration and thus, we cannot exclude that some patients may have improved EF over time. However, there is no recommendation to suspend RASi even after EF normalization. The outcomes, except for mortality, and causes of death were extracted from the National Patient Registry. Although this registry has 100% coverage since it is mandatory, adjudication is not performed. Finally, observational data allow to investigate the association between an exposure and outcome, but not to assess causality. Thus, even if the positive control consistency analysis may suggest that similar results could be reproduced in a trial setting, our findings may be interpreted only as hypothesis-generating for future RCTs.
Conclusions
In HFrEF patients with age >80 years, RASi were relatively underused compared with in younger patients, despite similar association with reduced morbidity and mortality and no association with risk of syncope-related hospitalization. These results may be interpreted as hypothesis generating for RCTs on RASi in this elderly HFrEF subpopulation.
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